IRCT2016121020024N4 IRCT 2017-02-10 Vice chancellor for research, Tehran University of Medical Sciences High dose Rosuvastatin as an adjunctive treatment in acute exacerbation of chronic obstructive pulmonary disease High dose Rosuvastatin as an adjunctive treatment in acute exacerbation of chronic obstructive pulmonary disease, a randomized double blind clinical trial. 2017-01-30 anticipated 90 Complete https://irct.ir/trial/17770 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment. 2-3 Chronic obstructive pulmonary disease with acute exacerbation. Intervention 1: The drug group will receive Rosuvastain tablet (Ropixon ®), dose 40 mg, manufactured by Dr. ABIDI PHARMACEUTICAL LABORATORY. The patients will receive the drug, once daily (first dose on the first day of admission), for 14 days. Intervention 2: The placebo group will receive a tablet with exact shape of Rosuvastain tablet provided by Dr. ABIDI PHARMACEUTICAL LABORATORY. The patients will receive the placebo, once daily (first dose on the first day of admission), for 14 days. The container of the drug and placebo tablets will be in same shape that the researchers, patients and clinicians could not discriminate the drug from placebo.